Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s

Amgen Inc., Biogen Inc., Gilead Inc. and Novo Nordisk A/S all have “very high” capacity for M&A activity, Moody’s Investors Service said in a report published Thursday.